本报讯(记者矫月)10月24日，全球特药领域生物制药公司益普生披露，该公司2025年前9个月的销售额 实现同比增长。 值得注意的是，益普生进一步上调了2025年全年财务指引，以固定汇率计算，总销售额同比增长约 10.0%(此前预期为高于7.0%)。 "本季度，我们也对医美方面的Ⅱ期LANTIC试验取得的数据感到十分欣喜，这项试验涉及一款同类首 创差异化长效分子IPN10200。随着我公司宣布拟收购ImCheck Therapeutics，我们将获得一项同类首创 资产，进而扩大我们的肿瘤研发管线。"DavidLoew表示。 2025年10月22日，益普生宣布就收购ImCheck Therapeutics事宜已签订最终股权收购协议，这是一家法 国私营生物技术公司，也是下一代肿瘤免疫疗法的开创性公司。此次收购重点在处于I/Ⅱ期的项目 ICT01，用于不适合接受一线治疗的急性髓系白血病(AML)，预计将于2026年启动IIb/Ⅲ期研究。ICT01 是一种靶向BTN3A(一种在癌症中广泛表达的关键免疫调节分子)的同类首创单克隆抗体，已于2025年7 月份获得美国食品药品监督管理局和欧洲药品管理局的孤儿药资格认定。 根据 ...

Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0%2 at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior guidance greater than 32. ...

IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacyData showed a rapid onset of action, peak effect superior to placebo, and a substantial majority of patients experiencing clinically significant longer duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity at Week 24Data to be presented at upcoming scientif ...